Search Results for “EC” – Page 211 – media

Replimune kickstarts Phase III melanoma trial studying RP1 immunotherapy

Replimune has announced the first patient in the Phase III melanoma trial with its lead immunotherapy RP1 or vusolimogene oderparepvec has been dosed and randomised. The IGNYTE-3 study (NCT06264180) will investigate the use of RP1 plus Bristol Myers Squibb’s PD-1 inhibitor Opdivo (nivolumab) for patients with advanced melanoma who have progressed on anti-PD1 and anti-CTLA-4 therapy, or who are ineligible for anti-CTLA-4 therapy. Massachusetts-based biotech Replimune’s CMO Kostas Xynos stated that the trial will serve to, “advance of our planned BLA submission of RP1 in advanced melanoma later this year”. In spite of slowing research, the wider oncolytic virus-based market has been projected to grow from $114mn in 2023 to $2.4bn in 2029 according to GlobalData analyst Kevin Marcaida. Marcaida expects that within this period, Replimune’s RP1 could claim a 74% market share. The IGNYTE-3 trial comes as Replimune continues a downward financial trend. Despite announcing $100m in private placement ...
- Source: drugdu
- 60
- August 16, 2024
Kezar stalls solid tumour trial to focus on autoimmune disease candidate

Clinical stage biopharma Kezar Life Sciences will drop its Phase I solid tumour drug to streamline focus on its lead autoimmune disease drug zetomipzomib. The San Francisco-based biotech shared this update in its 2Q financial results. The candidate, dubbed KZR-261, was being investigated in a Phase I trial (NCT05047536) in patients with solid tumours. Of the 61 enrolled patients, five experienced stable disease for four months or longer, with two of these patients experiencing stable disease for a year or longer. No objective responses have been reported. Enrolment in the trial has been halted, but the 61 patients will continue to have access to KZR-261. All eyes will now be on zetomipzomib, a selective immunoproteasome inhibitor. The candidate is being evaluated in a Phase IIb PALIZADE clinical trial (NCT05781750) for lupus nephritis and a Phase IIa PORTOLA clinical trial (NCT05569759) for autoimmune hepatitis. Everest Medicines secured the Greater China, South ...
- Source: drugdu
- 69
- August 16, 2024
International researchers use shear waves to map blood vessel structures

Researchers from King’s College London’s (KCL) School of Biomedical Engineering and Imaging sciences, along with partners at the University of Michigan, the Institut national de la santé et de la recherche médicale in Paris, Norway and Germany, are using shear waves to map blood vessel structures to improve treatments for tumours and other medical conditions. Findings published in Science Advances could improve cancer treatment and potentially improve drug delivery while helping researchers better understand tumours. Michigan and KCL experts developed a new theory using MRI-based elastography imaging to study how shear waves travel through tissue. By analysing them, researchers are able to measure the architecture of blood vessels non-invasively using readily available clinical imaging devices. Shear waves store information about the materials they pass through, including tissue stiffness, which can help diagnose diseases. The method allows researchers to see tiny blood vessels that are usually too small to detect and ...
- Source: drugdu
- 55
- August 16, 2024
Study finds AI reduces underdiagnosis of Black patients with common heart failure

A study led by King’s College London (KCL) has revealed that Black patients are less likely to be underdiagnosed with a common type of heart failure when using artificial intelligence (AI), compared to in routine practice. The research, funded by the British Heart Foundation, could help researchers understand the extent of heart failure with preserved ejection fraction (HFpEF) underdiagnosis across ethnicities, as well as reduce bias and improve diagnoses. Heart failure is estimated to affect more than one million people in the UK, 50% of whom have HFpEF, which occurs when the heart pumps out blood normally but cannot fill up as well, leading to signs and symptoms of failure such as breathlessness, fatigue and dizziness. Using an AI algorithm called Natural Language Processing (NLP), which reads and understands medical text and analyses electronic medical records, researchers identified nearly 1,973 patients who met the current European Society of Cardiology guidelines ...
- Source: drugdu
- 74
- August 16, 2024
BioPharma Expo JAPAN

Organiser：Reed Exhibitions Time：July 9th – 11th, 2025 address：3-21-1 Ariake, Koto-ku, Tokyo 135-0063, Japan Exhibition hall：Tokyo Big Sight International Exhibition Center Product range: Pharmaceutical Raw Materials and Ingredients: Pharmaceutical raw materials, APIs (Active Pharmaceutical Ingredients), intermediates, additives, functional raw materials, natural extracts, fine chemicals, business outsourcing/contract manufacturing/OEM, formulations, various analytical services and equipment, as well as other raw materials, related services, and technologies. Biopharmaceuticals: Laboratory equipment/reagents, biologics, drug discovery and development, biotechnology, genomics, etc. About BioPharma Expo JAPAN： BioPharma Expo, held in Tokyo, Japan, is the largest biopharmaceutical technology exhibition in the country. It encompasses research and development technology, manufacturing technology, and contract services. It attracts visitors, exhibitors, and professionals from various fields of the biopharmaceutical technology sector from all over the globe.
- Source: drugdu
- 216
- August 16, 2024
【EXPERT Q&A】Do foreign trade without import and export rights are there other ways to export?

Drugdu.com expert’s response: When foreign trade enterprises do not possess import and export rights, there are indeed alternative methods to achieve exports. These methods primarily encompass: I. Export Under Billing This refers to units without import and export rights using the name of another import and export company for export purposes. The specific operational process is as follows: 1.Purchase of Export Documents: Acquire a set of export customs declaration documents, which will be used for customs clearance procedures. 2.Submission of Customs Declaration Materials: Submit the purchased customs declaration materials to a customs broker or freight forwarder for customs clearance. Once the goods are successfully declared and released, the process of export under billing is completed. 3.Handling of Customs Clearance Documents: The information used for customs declaration may differ from the header company for customs clearance documents provided to the recipient at the destination port, but documents must be consistent, meaning ...
- Source: drugdu
- 77
- August 16, 2024
Cell adhesion and starvation found to be key drivers of pattern formation in keratinocytes

Cell-cell adhesion-induced patterning in keratinocytes can be explained by just starvation and strong adhesion, Hokkaido University researchers find. Fingerprints are one of the best-recognised examples of pattern formation by epithelial cells. The primary cells in the epithelium are the keratinocytes, and they are known to form patterns at the microscopic and macroscopic levels. While factors affecting this pattern formation have been reported, the exact mechanisms underlying the process are still not fully understood. A team of researchers, led by Associate Professor Ken Natsuga at the Faculty of Medicine, Hokkaido University, have revealed that cell-cell adhesion governs pattern formation in keratinocytes. Their findings were published in the journal Life Science Alliance. Ken Natsuga, Associate Professor, Faculty of Medicine, Hokkaido University, said, “In this study, we used an immortalized keratinocyte cell line, called HaCaT, which retains all the properties of normal keratinocytes. In order to ensure that our findings were accurate, we ...
- Source: drugdu
- 68
- August 15, 2024
US judge denies initial attempt by Novartis to block generic Entresto launch

Novartis’s bid to block the launch of a biosimilar for its best-selling drug Entresto (sacubitril/valsartan) got off to a faltering start, as the drugmaker failed to convince a US court that MSN Pharmaceuticals’ (MSNPI) copycat infringed on a patent. Richard Andrews, district judge for the District of Delaware, ruled the likelihood that Novartis would win the lawsuit was not high enough, meaning a preliminary injunction was not granted. While Andrews stated that stopping MSNPI’s generic launch was not justified, he did order a temporary 72-hour halt while Novartis goes to the US Court of Appeal to seek an injunction, as per a 12 August court document first released by Reuters. The hearing is part of a lawsuit initiated by Novartis to fend off MSNPI’s generic – which received US Food and Drug Administration (FDA) approval last month – to protect sales for its heart failure blockbuster. Novartis’s reference drug was ...
- Source: drugdu
- 61
- August 15, 2024
VIETNAM MEDIPHARM EXPO

Organiser：VIETFAIR, Vietnam Time：May 8th – 11th, 2025 address：91 Tran Hung Dao St., Hoàn Kiếm, Hanoi, Vietnam Exhibition hall：Cultural Friendship Palace Product range: Medical Products: Medical equipment and instruments, medical consumables, medical dressings, surgical equipment, rescue equipment, diagnostic medical equipment and supplies, ENT equipment, dental products, equipment, and supplies, medical health products and equipment, medical institution and laboratory technology equipment, medical information and technology exchange, beauty instruments, etc. Pharmaceutical Equipment: Pharmaceutical production equipment and technology, pharmaceutical packaging equipment, pharmaceutical packaging materials, pharmaceutical production, cleaning, disinfection, and allocation systems, etc. Laboratory Equipment: Optical instruments and equipment, microscopes, optical image processing, electronic measuring instruments, multimeters, electronic probes, electronic simulation systems, microcontroller development systems, image analysis and processing systems, etc. Analytical Instruments: Optical analytical instruments, mass spectrometers, spectrographs, chromatographs, wave meters, spectrum analyzers, various portable instruments, surface analysis instruments, nuclear analysis instruments, elemental analysis instruments, process analysis instruments, compositional analysis instruments, injection analysis ...
- Source: drugdu
- 211
- August 14, 2024
Study suggests COVID-19 vaccination lowers incidence of arterial thromboses

Researchers from the Universities of Cambridge, Bristol and Edinburgh have suggested that COVID-19 vaccinations could lower the incidence of arterial thromboses. The study, published in Nature Communications, was supported by the British Heart Foundation (BHF) Data Science Centre at Health Data Research UK. Researchers analysed the de-identified health records of 46 million adults from GP practices, hospital admissions and death records in England between December 2020 and January 2022, provided by NHS England. The team compared the incidence of cardiovascular diseases (CVDs) following COVID-19 vaccination with the incidence before or without vaccination during the first two years of the vaccination programme. CVD affects around seven million people in the UK and is a significant cause of disability and death. Overall, the study revealed that the incidence of arterial thromboses, such as heart attacks and strokes, which affect 200,000 people in the UK every year combined, was up to 10% lower ...
- Source: drugdu
- 60
- August 14, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.